Clinical Trials | June 16, 2026
Lilly’s Jaypirca cuts risk of disease progression or death by 45% in landmark trial
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jaypirca is making waves in the fight against B-cell malignancies
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
Lifts full-year outlook as obesity drug boom accelerates
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
